BioLife Solutions acquired by Repligen: fairness opinion
Announced July 22, 2026 · Merger ·
DEFM14A filed September 4, 2026
Enterprise value
$1.5B
EV / LTM EBITDA
60.0x
EBITDA $25.0M · 26% margin
EV / LTM revenue
15.59x
revenue $96.2M
DCF discount rate
12.5%–15.0%
Deal terms
Consideration—
Price per share—
Premium—
Premium basis—
StructureMerger
Termination fee—
Reverse termination fee—
Go-shopNone
Outside date—
FilingDEFM14A · EDGAR index
3,000+ healthcare deal-level valuation multiples
The Valuation database includes financial details for more than 3,000 healthcare M&A transactions, private and public, with deal-level multiples, categorized by segment, type, and year.
Management projections
| Projection year | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | $115M | $143M | $173M | $208M | $248M | 21.2% |
| Revenue growth | 19.5% | 24.3% | 21.0% | 20.2% | 19.2% | |
| EBITDA | $32.0M | $49.0M | $68.0M | $94.0M | $124M | 40.3% |
| EBITDA growth | 28.0% | 53.1% | 38.8% | 38.2% | 31.9% | |
| EBITDA margin | 28% | 34% | 39% | 45% | 50% | |
| Implied EV / EBITDA | 46.9x | 30.6x | 22.1x | 16.0x | 12.1x |
Year-1 growth is against LTM at announcement ($96.2M revenue, $25.0M EBITDA); later years are year over year.
Other Diagnostics / Life Sciences fairness opinions
- Lantheus / Curium 2026 · 14.1x EV/EBITDA
- Personalis / Tempus 2026
- BIO-TECHNE / Merck 2026 · 26.2x EV/EBITDA
- Masimo / Danaher 2026 · 21.2x EV/EBITDA
- Exact Sciences / Abbott 2025 · 44.2x EV/EBITDA
- Enzo Biochem / Battery Ventures 2025